michael pollock is President of Reynolds Pollock & Associates, a health outcomes research and market access strategy consulting company. Michael has a unique background in the biopharmaceutical industry, having held senior positions both in Sales & Marketing and in Health Economics.

In addition to his role as President of Reynolds Pollock & Associates, Michael is an Adjunct Professor at the Rady School of Management at the University of California, San Diego, where he teaches a course in the Executive MBA Program on the Structure and Strategy of the Biotechnology Industry.

Immediately prior to founding Reynolds Pollock & Associates, Michael was Vice President of Global Health Economics at Biogen Idec, with worldwide responsibility for health economics strategy and research, across the entire portfolio of marketed and pipeline products.

Before joining Biogen Idec, Michael was Vice President, Global Therapeutic Markets at Elan Pharmaceuticals, with responsibility for the sales and marketing of the company's Pain and Hospital Products. Michael joined Elan from Oncology Therapeutics Network (OTN), a division of Bristol-Myers Squibb, where he was Vice President, Sales & Marketing and Information Services.

Prior to joining OTN, Michael spent several years in health outcomes strategy and research consulting, having founded Optimal Strategic Decisions Inc., a health outcomes research and market access strategy consulting company.

In addition, Michael was previously Director, Health Economics at Glaxo Wellcome Research & Development, in the U.K., with worldwide responsibility for health economics.